Micro Market Research
+1-888-502-0539
US/CAN Toll Free

You are here :   Home     Healthcare     Pharmaceuticals     Drug formulations    
Real Time Market Research & Industry Analysis - MicroMarketMonitor

Global Acute lymphoblastic leukemia (ALL) Market Research Report

  • Report Code: AC 1000
  • Publish Date: Upcoming
  
Description
Table of Contents
Customer Intelligence
Summary
Inquiry Before Buying Ask for Discount
Acute lymphoblastic leukemia (ALL) and its peer markets - T-cell Lymphoma, Non-Hodgkin lymphoma, Chronic myeloid leukemia (CML), Chronic lymphocytic leukemia (CLL), Acute myeloid leukemia (AML), Multiple myeloma, Lymphoplasmacytic lymphoma, Adult T-cell leukemia, Hairy-cell leukemia and 3 other type markets - adds up to total Haematopoietic and lymphoid tissues Cancers market.

Acute lymphoblastic leukemia (ALL) can be segmented by Submarkets, Geographies and Companies. Submarkets of this market are Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems (CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Chromatography Instruments, Next Generation Sequencing (NGS), Proteomics, Marketed Drugs and Pipeline Drugs. Geographies of this market are USA, Canada, United Kingdom, Germany, France, Italy, Spain and Japan. Companies of this market are Erytech Pharma, Genzyme Corporation, Sigma-Tau Pharmaceuticals, Inc., Talon Therapeutics, Inc., Pfizer Inc, Glaxosmithkline Plc, Seattle Genetics, Inc., Novartis AG, Sanofi-Aventis U.S., Amgen Inc., ImmunoGen, Inc., Syntrix Biosystems, Inc., Delta-Fly Pharma, Inc. and Spectrum Pharmaceuticals, Inc..

 

Key Questions Answered

  • What are market estimates and forecasts; which of Acute lymphoblastic leukemia (ALL) markets are doing well and which are not?
  • What is the competitive landscape; How companies like Erytech Pharma, Genzyme Corporation and Sigma-Tau Pharmaceuticals, Inc. doing in Acute lymphoblastic leukemia (ALL)?
  •  

    What makes our report unique?

    • This reports provides most granular segmentation on Chromatography, E-Clinical Trial Solutions, Wireless Health and Clinical Trial Management Systems (CTMS).
    • This report provides market sizing and forecast for the Acute lymphoblastic leukemia (ALL) market. It also provides market sizing and forecast along with the drivers/inhibitors/opportunity analysis for each of the micro markets.
    • The report provides deep dive competitive landscape covering the top players such as Erytech Pharma, Genzyme Corporation, Sigma-Tau Pharmaceuticals, Inc. and Talon Therapeutics, Inc..
    • The reports provides benchmarking insight on the top players Erytech Pharma, Genzyme Corporation, Sigma-Tau Pharmaceuticals, Inc. and Talon Therapeutics, Inc..
    • The report provide competitive intelligence on Erytech Pharma, Genzyme Corporation, Sigma-Tau Pharmaceuticals, Inc. and Talon Therapeutics, Inc..
    •  

      Audience for this report

      • Global Acute lymphoblastic leukemia (ALL) companies
      • Manufacturing Companies
      • Traders, distributors, and suppliers
      • Governmental and research organizations
      • Associations and industry bodies
      • Technology providers
      •  

        Top developments

        • ERYTECH Pharma entered into an agreement with Orphan Europe (France).
        • Talon Therapeutics received approval from the U.S. FDA for its product Marqibo.
        • The company announced direct distribution.
        • Talon Therapeutics reached an agreement with the U.S. FDA .
        • Talon Therapeutics received FDA acceptance.
        • European Medicines Agency accepted Pfizer's regulatory submissions.
        • ERYTECH Pharma signed an exclusive agreement with Teva
        • The company received an approval from U.S. FDA for the manufacturing of L-asparaginase.
        • ERYTECH Pharma completed the Phase II clinical trial for GRASPA.
        • Pfizer, Inc. proposed regulatory submissions for a Marketing Authorization Application


1 Introduction
1.1 Analyst Insights
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
2 Executive Summary
3 Market Overview
4 By Submarkets
4.1 Chromatography
4.2 E-Clinical Trial Solutions
4.3 Wireless Health
4.4 Clinical Trial Management Systems (CTMS)
4.5 Healthcare IT outsourcing
4.6 Immunoassay
4.7 Digital Pathology
4.8 Chromatography Instruments
4.9 Next Generation Sequencing (NGS)
4.10 Proteomics
4.11 Marketed Drugs
4.12 Pipeline Drugs
5 By Geographies
5.1 USA
5.2 Canada
5.3 United Kingdom
5.4 Germany
5.5 France
5.6 Italy
5.7 Spain
5.8 Japan
6 By Companies
6.1 Erytech Pharma
6.2 Genzyme Corporation
6.3 Sigma-Tau Pharmaceuticals, Inc.
6.4 Talon Therapeutics, Inc.
6.5 Pfizer Inc
6.6 Glaxosmithkline Plc
6.7 Seattle Genetics, Inc.
6.8 Novartis AG
6.9 Sanofi-Aventis U.S.
6.10 Amgen Inc.
6.11 ImmunoGen, Inc.
6.12 Syntrix Biosystems, Inc.
6.13 Delta-Fly Pharma, Inc.
6.14 Spectrum Pharmaceuticals, Inc.

Please fill in the form below to receive a free copy of the Summary of this Report
















Global Acute lymphoblastic leukemia (ALL) Market Research Report

* Enter the text from the image to the text box :

refresh captcha
Custom Market Research Services
We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
PRODUCT TITLE PUBLISHED
Hyper-CVAD regimen Hyper-CVAD regimen
Hyper-CVAD regimen and CALGB 8811 regimen, Linker Regimen,
Upcoming
CALGB 8811 regimen CALGB 8811 regimen
CALGB 8811 regimen and Hyper-CVAD regimen, Linker Regimen,
Upcoming
Linker Regimen Linker Regimen
Linker Regimen and Hyper-CVAD regimen, CALGB 8811 regimen,...
Upcoming
Nucleoside Metabolic Inhibitors (Clolar + Nelarabine) Nucleoside Metabolic Inhibitors (Clolar + Nelarabine)
Nucleoside Metabolic Inhibitors (Clolar + Nelarabine) and Hyper-CVAD regimen,
Upcoming
Oncaspar (Pegaspargase) Oncaspar (Pegaspargase)
Oncaspar (Pegaspargase) and Hyper-CVAD regimen, CALGB 8811...
Upcoming
Phase II Phase II
Phase II and Phase I and Phase III adds up to total Pipeline Drugs market. ...
Upcoming
Phase III Phase III
Phase III and Phase I and Phase II adds up to total Pipeline Drugs market. ...
Upcoming
7 of 7 items
7 reports | Show
Connect With Us
US/CAN : +1-888-502-0539